Hotchkis & Wiley Capital Management LLC Boosts Holdings in LivaNova PLC $LIVN

Key Points

• Hotchkis & Wiley Capital Management has increased its stake in LivaNova PLC by 100.7%, now holding approximately 1,003,000 shares valued at about $39.40 million.
• LivaNova's latest earnings report showed earnings per share of $1.05, surpassing analysts' expectations of $0.84, with revenues reaching $352.50 million.
• Wall Street analysts have a favorable outlook on LivaNova, with most rating it as a "Buy" or higher and an average price target of around $59.71.

Hotchkis & Wiley Capital Management LLC lifted its stake in LivaNova PLC (NASDAQ:LIVN - Free Report) by 100.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,003,000 shares of the company's stock after purchasing an additional 503,350 shares during the quarter. Hotchkis & Wiley Capital Management LLC owned 1.84% of LivaNova worth $39,398,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently modified their holdings of the company. UMB Bank n.a. raised its position in shares of LivaNova by 340.5% in the 1st quarter. UMB Bank n.a. now owns 837 shares of the company's stock worth $33,000 after purchasing an additional 647 shares during the last quarter. CWM LLC raised its position in shares of LivaNova by 52.3% in the 1st quarter. CWM LLC now owns 871 shares of the company's stock worth $34,000 after purchasing an additional 299 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its position in LivaNova by 415.4% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,469 shares of the company's stock worth $58,000 after buying an additional 1,184 shares during the last quarter. Russell Investments Group Ltd. raised its position in LivaNova by 17.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock worth $70,000 after buying an additional 219 shares during the last quarter. Finally, Central Pacific Bank Trust Division lifted its stake in LivaNova by 7.0% during the 1st quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company's stock valued at $173,000 after acquiring an additional 290 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

LivaNova Stock Performance

Shares of LIVN stock traded down $0.10 during trading hours on Wednesday, reaching $56.49. 474,810 shares of the company traded hands, compared to its average volume of 708,177. LivaNova PLC has a 12-month low of $32.48 and a 12-month high of $57.35. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09. The company has a market cap of $3.08 billion, a P/E ratio of -14.52 and a beta of 0.92. The firm has a 50-day moving average price of $46.88 and a 200 day moving average price of $43.15.

LivaNova (NASDAQ:LIVN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, beating analysts' consensus estimates of $0.84 by $0.21. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The firm had revenue of $352.50 million for the quarter, compared to analysts' expectations of $332.20 million. During the same period in the previous year, the firm earned $0.93 EPS. The business's quarterly revenue was up 10.6% on a year-over-year basis. As a group, sell-side analysts predict that LivaNova PLC will post 2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LIVN has been the subject of a number of research analyst reports. Wolfe Research raised shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective for the company in a report on Tuesday, May 20th. Robert W. Baird boosted their target price on shares of LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Barclays boosted their target price on shares of LivaNova from $55.00 to $58.00 and gave the company an "equal weight" rating in a research note on Thursday, August 21st. Needham & Company LLC reiterated a "buy" rating and set a $64.00 target price on shares of LivaNova in a research note on Tuesday, May 13th. Finally, Wall Street Zen upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $59.71.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.